Johnson & Johnson CEO Advocates Faster Approvals and R&D Partnerships to Strengthen Americas Innovation
Johnson & Johnson’s CEO laid out a plan to reinforce the Americas’ life sciences leadership by advocating streamlined regulatory pathways and deeper public–private R&D partnerships to accelerate new therapies. He highlighted efforts to bolster supply-chain resilience and expand clinical trial networks across North and South America.
1. CEO Addresses Americas Health Summit
At the Americas Health Summit, Johnson & Johnson’s CEO argued that maintaining global biopharma leadership requires policy reforms to speed drug approvals and enhance collaboration between government agencies and industry. He emphasized the need for agile regulatory frameworks to reduce development timelines for novel therapies.
Related News
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
SLAB
Silicon Labs SoC Powers 500,000 Wi-SUN Module Shipment for India Grid
SLAB•
CNS
Cohen & Steers Partners with J.P. Morgan on Short-Duration Hybrid Credit Fund Expansion
CNS•
JEPQ
JPMorgan ETF Offers 9.5% Yield with Hidden ELN Counterparty Risk
JEPQ•
Sources
F